RODRIGO GUIMARÃES QUEIROZ

RODRIGO GUIMARÃES QUEIROZ

Página do item completo

Resultados de Busca

Agora exibindo 1 - 10 de 12

State of the art and current advances on protein cross-linking by irradiation: protein based nanocarriers and bioactive nanoparticles
2017 - VARCA, G.H.C.; MOHAMED, L.B.; FAZOLIN, G.N.; BATISTA, J.G.D.S.; QUEIROZ, R.G.; LUGAO, A.B.; NAVARRO MARQUES, F.A.; FERREIRA, A.H.
The highlighted role of protein and peptide based delivery systems relies upon the possibility to develop biocompatible drug carriers featuring site specific delivery, biological affinity among unique advantages. Recently, a technique for protein nanostructuring by the use of radiation has been recently reported by our group. Advantages of the use of radiation over conventional methods are related to the possibility to achieve protein cross-linking and sterilization in a single step, as well as the capacity to allow the design of nanocarriers without the need of monomers or toxic cross-linkers. This work reports the use of high energy irradiation towards the design of size-controlled protein-based nanocarriers and bioactive nanoparticles, using bovine serum albumin (BSA) and papain as model protein and protease, respectively, including the state of the art and current advances of the technology. The technique implies on protein desolvation/solvation techniques followed by cross-linking by EB radiation or -irradiation alone, although nanoparticles were also achieved in absence of the cosolvents. Size-controlled BSA nanocarriers were manufactured up to 80 nm and papain bioactive nanoparticles up to 12 nm, as determined by dynamic light scattering. Nanocarrier morphology was evaluated by and negative staining transmission electron microscopy. Protein cross-linking and changes in aromatic the amino acids were evaluated by fluorescence measurements. Biocompatibility experimentswere also performed by means of cytotoxicity and cytokines production. The potential of the systems for the delivery of radiopharmaceuticals or chemotherapeutic agents were also assayed, using technetium or Paclitaxel respectively. In conclusion, the technique allowed the production of biocompatible and bioactive protein nanoparticles suitable for the administration of radiopharmaceuticals and chemotherapeutic agents.
In vitro and in vivo antitumor effects of Azidothymidine in a human multiple myeloma cell line
2012 - LEVY, DEBORA; RUIZ, JORGE L.; BROCARDO, GRACIELA; FERREIRA, ADILSON; QUEIROZ, RODRIGO; MARIA, DURVANEI; BYDLOWSKI, SERGIO; PEREIRA, JULIANA
Azidothymidine (AZT) is an antiretroviral nucleoside analogous inhibitor of reverse transcriptase with known effects on cell proliferation, apoptosis, and angiogenesis Multiple myeloma is a severe disease and one of the steps involved in the malignant transformation of plasma cells is the activation of the nuclear factor kappa B (NF-κB) pathway.
Radiation-synthesized protein-based drug carriers: Size-controlled BSA nanoparticles
2016 - QUEIROZ, R.G.; VARCA, G.H.C.; KADLUBOWSKI, S.; ULANSKI, P.; LUGAO, A.B.
Irradiation as an alternative route for protein crosslinking: Cosolvent free BSA nanoparticles
2016 - VARCA, GUSTAVO H.C.; QUEIROZ, RODRIGO G.; LUGAO, ADEMAR B.
Radiochemical and biological evaluation of Ter-Cys-RGD derivarive labeled with the precursor [sup(99m)Tc(Hsub(2)O)sub(3)(CO)sub(3)]sup(+)
2007 - TEODORO, RODRIGO; FAINTUCH, BLUMA L.; QUEIROZ, RODRIGO G.; MURAMOTO, EMIKO; MORGANTI, LIGIA; NASCIMENTO, NANCI do
sup(99m)Tc labeling of annexin fragment by two different techniques for detection of apoptosis in cancer
2007 - FAINTUCH, BLUMA L.; TEODORO, RODRIGO; QUEIROZ, RODRIGO G.; MURAMOTO, EMIKO; CHURA-CHAMBI, ROSA M.; MORGANTI, LIGIA; NASCIMENTO, NANCI
sup(99m)Tc-Hynic-RGD analog for monitoring of integrin expression in ischemic animal model
2007 - QUEIROZ, RODRIGO G.; FAINTUCH, BLUMA L.; TEODORO, RODRIGO; MURAMOTO, EMIKO
Evaluation of sup(99m)Tc-neurotensin analog using different chelators
2008 - FAINTUCH, BLUMA; TEODORO, RODRIGO; QUEIROZ, RODRIGO; FAINTUCH, SALOMAO
Initial studies of radiolabeling and biodistribution of peptide p160 analog with technetium-99m
2008 - QUEIROZ, RODRIGO; FAINTUCH, BLUMA; FAINTUCH, SALOMAO; TEODORO, RODRIGO
Azidothymidine is effective against human multiple myeloma
2013 - PEREIRA, JULIANA; LEVY, DEBORA; RUIZ, JORGE L.M.; BROCARDO, GRACIELA A.; FERREIRA, KLEBER A.; COSTA, RENATA O.; QUEIROZ, RODRIGO G.; MARIA, DURVANEI A.; HALLACK NETO, ABRAHÃO E.; CHAMONE, DALTON A.F.; BYDLOWSKI, SÉRGIO P.
Azidothymidine (AZT) is an antiretroviral drug that affects cell proliferation, apoptosis, and the NF-κB pathway. As multiple myeloma (MM) presents with constitutive activation of NF-κB, we analyzed the effect of AZT on human MM cell lines. We evaluated the cytotoxic effect of AZT in human MM cell lines sensitive (8226/S) or resistant to doxorubicin (8226/DX5) and human T cell lymphoblast-like cells, uterine sarcoma cells, and HUVEC using MTT assay. Cytotoxicity was also evaluated in vivo in nude mice xenografted with 8226/S tumor. The effect of AZT on the expression of genes involved in cell proliferation, apoptosis, angiogenesis, and the NF-κB pathway was analyzed in the xenografts using real-time polymerase chain reaction. AZT was effective against both 8226/S and 8226/DX5 cells in a dose and time-dependent manner (p = 0.02) in vitro and promoted cell cycle arrest in S phase in these cells. The tumor volume was lower in mice treated with AZT compared to untreated mice (p = 0.0003). AZT down-regulated the pro-proliferative genes encoding AKT1, MYC, STAT1, MAPK8, MAPK9, CCL-3, Bcl-3, and cyclin D2; pro-angiogenenic genes encoding VEGF and IL8; and genes involved in cell adhesion (ICAM1 and FN1) and the NF-κB pathway. AZT up-regulated the expression of tumor suppressor gene FOXP1 and the pro-apoptotic genes encoding BID, Bcl-10, and caspase-8. Thus, we demonstrated the cytotoxic effect of AZT in human MM cell lines for the first time. Our data may provide the rationale for future clinical trials of AZT for treating MM.